Cystatin C Kidney Gap Signals Higher Death Risk

A meta-analysis of more than 860,000 people links large differences between two kidney tests to higher mortality and heart failure.

Updated on Nov. 20, 2026 in Diseases — General

Cystatin C Kidney Gap Signals Higher Death Risk

A meta-analysis of 821,327 outpatients found that when cystatin C-based kidney function estimates ran at least 30% below creatinine-based estimates, participants had higher rates of death and heart failure. The same pattern was common among 39,639 hospitalized patients, about 35% of whom showed a large negative difference.

Why it matters

Creatinine-based kidney function tests are widely used to guide clinical decisions, so a sizable gap with cystatin C may flag people whose risk is underestimated by standard testing. The findings suggest that comparing both measures could help clinicians identify patients who warrant closer monitoring.

Among 23 outpatient cohorts, the share with a large negative difference ranged from 2.8% to 49.8%, and mortality rates were 28.4 vs 16.8 per 1000 person-years. Whether these associations reflect causal effects of kidney function or measurement factors remains unresolved.

The players

Chronic Kidney Disease Prognosis Consortium

The Chronic Kidney Disease Prognosis Consortium is an international collaboration of research cohorts that pools individual participant data to study kidney disease outcomes.

The details

Researchers pooled participant-level data from 23 outpatient cohorts and 2 inpatient cohorts in the Chronic Kidney Disease Prognosis Consortium, with all participants having concurrent creatinine and cystatin C measurements. Models were adjusted for demographics, comorbidities, body mass index, creatinine-based eGFR category, and albuminuria, and outcomes were tracked over an average of 11 years of follow-up.

Timeline

  1. Outcomes in the outpatient cohorts were tracked over an average follow-up of 11 years.

Health Landscape

The findings extend a broader shift in kidney medicine toward combining creatinine and cystatin C rather than relying on creatinine alone, a direction pursued by pooled consortium analyses of eGFR equations. The results reflect how large multi-cohort studies are increasingly used to test whether combined markers improve risk identification across diverse populations.

For patients with chronic kidney disease, a large gap between the two kidney tests may prompt doctors to review medications and monitoring plans more closely. The findings do not yet establish that changing treatment based on this gap improves survival, so patients should discuss their results with a clinician.

The takeaway

Doctors and patients may benefit from asking whether both creatinine and cystatin C results are available when kidney function is assessed. Discussing a large difference between the two with a clinician can help determine whether additional monitoring is appropriate.

Further reading

For related context, explore more Diseases — General coverage on Wisevoter.

Source note: This article includes information reported by Ajmc.